Alembic Pharmaceuticals

Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December, 2025

06 Feb, 2026 | 03:20pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets

06 Feb, 2026 | 11:31am • Source: BSE

Please find attached the intimation of appointment of Mr. Raj Kumar Baheti (DIN:00332079) as Non-Executive Non Independent Director of the Company.

05 Feb, 2026 | 04:15pm • Source: BSE

Please find attached herewith the Revised Investor Presentation

05 Feb, 2026 | 03:12pm • Source: BSE

Unaudited financial results for the quarter and nine months ended 31st December, 2025

05 Feb, 2026 | 02:22pm • Source: BSE

Please find attached the investor presentation

05 Feb, 2026 | 02:16pm • Source: BSE

PFA the press release

05 Feb, 2026 | 02:13pm • Source: BSE

Please find attached Unaudited Financial Results for the quarter and nine months ended 31st December, 2025

05 Feb, 2026 | 02:00pm • Source: BSE

Please find attached herewith Newspaper Publication related to Loss of Share Certificate

03 Feb, 2026 | 02:47pm • Source: BSE

Change in Senior Managerial Personnel

31 Jan, 2026 | 07:08pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.

27 Jan, 2026 | 12:36pm • Source: BSE

Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and...

20 Jan, 2026 | 10:28am • Source: BSE

Alembic Pharmaceuticals Limited announces USFDA Tentative approval for Bosutinib Tablets, 400 mg.

12 Jan, 2026 | 12:07pm • Source: BSE

Please find attached herewith the Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st December, 2025

05 Jan, 2026 | 05:04pm • Source: BSE

Intimation of Closure of Trading Window.

26 Dec, 2025 | 12:20pm • Source: BSE

Alembic Pharmaceuticals Limited announces USFDA approval for Travoprost Ophthalmic Solutions

18 Dec, 2025 | 11:00am • Source: BSE

Please find attached Newspaper Publication of Special Window for re-lodgement of transfer of physical shares.

15 Dec, 2025 | 04:37pm • Source: BSE

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol...

11 Dec, 2025 | 12:13pm • Source: NSE

Alembic Pharmaceuticals Limited receives USFDA Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%

11 Dec, 2025 | 11:53am • Source: BSE

Please find attached herewith a copy of advertisement related to notice of loss of equity share certificate.

09 Dec, 2025 | 06:48pm • Source: BSE